Technical Analysis for IMMX - Immix Biopharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | -3.85% | |
| Pocket Pivot | Bullish Swing Setup | -3.85% | |
| Volume Surge | Other | -3.85% | |
| Outside Day | Range Expansion | -3.85% | |
| Up 3 Days in a Row | Strength | -3.85% | |
| Upper Bollinger Band Touch | Strength | -3.85% | |
| 20 DMA Support | Bullish | 2.94% | |
| Pocket Pivot | Bullish Swing Setup | 2.94% | |
| Inside Day | Range Contraction | 2.94% | |
| BB Squeeze Ended | Range Expansion | 2.94% |
| Alert | Time |
|---|---|
| Rose Above Upper Bollinger Band | about 2 hours ago |
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Possible Pocket Pivot | about 2 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/28/2024
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. It is developing IMX-110 that is in Phase Ib/IIa clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. The company has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase Ib clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc. was incorporated in 2012 and is based in Los Angeles, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Autoimmune Disease Inflammation Colorectal Cancer Sarcoma Ulcerative Colitis Abdominal Pain Crohn's Disease Soft Tissue Sarcoma
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 7.75 |
| 52 Week Low | 1.26 |
| Average Volume | 118,911 |
| 200-Day Moving Average | 2.22 |
| 50-Day Moving Average | 1.63 |
| 20-Day Moving Average | 1.67 |
| 10-Day Moving Average | 1.71 |
| Average True Range | 0.16 |
| RSI (14) | 58.85 |
| ADX | 20.34 |
| +DI | 28.97 |
| -DI | 14.23 |
| Chandelier Exit (Long, 3 ATRs) | 1.48 |
| Chandelier Exit (Short, 3 ATRs) | 1.95 |
| Upper Bollinger Bands | 1.83 |
| Lower Bollinger Band | 1.50 |
| Percent B (%b) | 0.96 |
| BandWidth | 19.73 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.01 |
| MACD Histogram | 0.0113 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.25 | ||||
| Resistance 3 (R3) | 2.24 | 2.08 | 2.18 | ||
| Resistance 2 (R2) | 2.08 | 1.97 | 2.09 | 2.15 | |
| Resistance 1 (R1) | 1.95 | 1.91 | 2.02 | 1.96 | 2.13 |
| Pivot Point | 1.80 | 1.80 | 1.83 | 1.80 | 1.80 |
| Support 1 (S1) | 1.67 | 1.69 | 1.73 | 1.68 | 1.51 |
| Support 2 (S2) | 1.51 | 1.62 | 1.52 | 1.49 | |
| Support 3 (S3) | 1.38 | 1.51 | 1.46 | ||
| Support 4 (S4) | 1.39 |
